Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

    NEXT STORY
    Beroni Group Announces Webcast from Biotech Showcase™ 2020 in San Francisco, USA
    PREV STORY
    Colorectal Cancer Therapeutics Market to reach USD 16.58 billion by 2026, Presence of Strong Oncology Portfolio to help Players Gain Competitive: Reports Fortune Business Insights™
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Retrophin Provides Corporate Update and 2020 Outlook

    author_avatar
    NASDAQ Market News

    Merit Medical Enters Strategic Alliance and Worldwide Distribution with NinePoint Medical

    SOUTH JORDAN, Utah, May 02, 2018 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), ...

    author_avatar
    NASDAQ Market News

    Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017

    LEXINGTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company ...

    author_avatar
    NASDAQ Market News